menu
    • menu
    [{"orgOrder":0,"company":"Triphase Accelerator","sponsor":"Catalent Pharma Solutions","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"TRPH-222","moa":"B-cell receptor CD22 (CD22)","graph1":"Oncology","graph2":"Phase I","graph3":"Triphase Accelerator","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Triphase Accelerator \/ Catalent Pharma Solutions","highestDevelopmentStatusID":"6","companyTruncated":"Triphase Accelerator \/ Catalent Pharma Solutions"},{"orgOrder":0,"company":"Triphase Accelerator","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"TRPH-222","moa":"B-cell receptor CD22 (CD22)","graph1":"Oncology","graph2":"Phase I","graph3":"Triphase Accelerator","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Triphase Accelerator \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Triphase Accelerator \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals by Triphase Accelerator

    Menu

    Triphase Accelerator

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Triphase Accelerator

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Triphase Accelerator

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : TRPH-222

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Catalent Pharma Solutions

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Triphase Accelerator and Catalent Biologics Announce Interim Results of a Dose Escalation Phase 1 Clinical Tri...

                            Details : TRPH-222 (CAT-02-106), is a novel antibody-drug conjugate (ADC) composed of an anti-CD22 monoclonal antibody modified to allow site-specific conjugation of a maytansine payload via a non-cleavable linker.

                            Product Name : Undisclosed

                            Product Type : Antibody-drug Conjugate

                            Upfront Cash : Inapplicable

                            May 18, 2020

                            Lead Product(s) : TRPH-222

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Catalent Pharma Solutions

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Triphase Accelerator

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Triphase Accelerator

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : TRPH-222

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Triphase Accelerator and Catalent Biologics Share Interim Results of a Dose Escalation Phase 1 Clinical Trial ...

                            Details : TRPH-222, Triphase Accelerator’s novel antibody-drug conjugate (ADC), has been safely dosed up to 7.5 mg/kg every three weeks in patients; dose escalation continues with the first patient now dosed at 10 mg/kg.

                            Product Name : Undisclosed

                            Product Type : Antibody-drug Conjugate

                            Upfront Cash : Inapplicable

                            May 18, 2020

                            Lead Product(s) : TRPH-222

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth